IL17A and SAPHO syndrome: Researchers have investigated SAPHO syndrome and ascertained that IL-17 inhibitors and IL-23 inhibitors exhibit promising efficacy in the management of refractory SAPHO syndrome, leading to significant improvement in patients’ acne symptoms (60, 61).